California · Nonprofit
QUANTUM LEAP HEALTHCARE COLLABORATIVE
QUANTUM LEAP HEALTHCARE COLLABORATIVE (California) receives grants from 18 organizations whose IRS filings report $2,668,971 to it, the largest being THE ALBERTSONS COMPANIES FOUNDATION ($730,000). 8 of them have funded it in more than one year.
- Revenue FY2024
- $46M
- Funders on record
- 18
- Grants received
- $2.7M
- Net assets
- $11M
What Quantum Leap Healthcare Collaborative does
Mission
The mission of quantum leap healthcare collarborative is to provide management and financial support to healthcare research organizations, particularly involving breast cancer research and treatment.
As stated on its FY2024 Form 990.
Programs
Ispy 2.2 - I-spy 2.2 uses a 'sequential multiple assignment randomized trial' (smart) design - that is both smart and adaptive. The trial consists of up to three blocks of treatment. The first, block a, includes novel targeted therapies, without standard chemotherapy. If a patient achieves a complete response after block a, they can avoid toxic chemotherapy and go directly to surgery. If they have residual cancer, or the treatment is found to have little effect halfway through the course of treatment, they are recommended to proceed to treatment in block b. In block b, patients are assigned a treatment regimen most likely to work for their subtype, often combined with chemotherapy since the risk of toxicity is more acceptable in patients with more resistant cancer. (continued on schedule o)if block b treatment is effective, the patient can skip additional chemotherapy and go to surgery. Only if they still have tumor left after block b, will the patientt get rescue therapy with doxorubicin and cyclophosphamide a chemotherapy regimen that has been around for decades. Average overhead booked to program in fy2024 = 36.9%
$31,082,090 spent$28,146,883 earned by the program56% of program spendingDcis - the re-evaluating conditions for active surveillance suitability as treatment: ductal carcinoma in situ (recast dcis) platform trial is a landmark phase 2 trial that is changing the lens through which we treat dcis. The study is aimed at preventing the progression of dcis to breast cancer and is evaluating three investigational endocrine therapy arms.with the objective to avoid over-treatment of low-risk dcis patients, this new trial offers dcis patients endocrine therapy with the intent to identify patients who are responsive to non-invasive treatment and have the option to omit surgery and be monitored via long-term active surveillance. (continued on schedule o)a key element in reducing over treatment of dcis is identifying biomarkers that reflect the risk of progression so that those with low-risk lesions are spared surgery. Recast dcis features the assessment of mri imaging and molecular-based biomarker analyses in addition to evaluating new investigational agents in this setting. If patients and their physicians agree, they may be able to stay on endocrine therapy for up to three years. Average overhead booked to program in fy2024 = 7.2%
$2,337,901 spent$3,517,864 earned by the program4% of program spendingPhase1b - pre I-spy is an open-label phase 1b platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-spy 2.2 trial and/or other oncology-based trials in a timely manner. The primary objectives of this platform trial are to determine the safety and tolerability of new agents/regimes in patients with certain advanced solid tumors and breast cancer while obtaining preliminary efficacy data of the new agents/regimes. The study was developed to help investigators and industry partners meet the safety qualifications necessary for participation in I-spy 2.2 (continued on schedule o) trial and/or other phase ii/iii studies. Average overhead booked to program in fy2024 = 7.00%
$271,185 spent$1,877,278 earned by the program0% of program spendingOther programs include breast cancer trials (bct) match, covid-19 trials, I-spy 2.0, endocrince optimization project (eop) trials, and one source ai.
$21,638,115 spent$8,948,949 earned by the program39% of program spending
The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $55,329,291.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2019 to 2020, from $17M to $47M (+180%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2020 23% · 2021 64% · 2022 37%. Grants only. Government contracts and fees sit inside program revenue.
2% of QUANTUM LEAP HEALTHCARE COLLABORATIVE’s revenue is contributions — more earned-revenue than three-quarters of its peers (21% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Board chair
Dave Mandelkern Ms
Chairman
As listed on its FY2024 Form 990.
The chief executive listed changed between the FY2018 and FY2019 filings.
Who funds it, year by year
2017 → 2023: the base broadened from 3 funders to 5 funders, grant income fell $168k → $132k.
8 of 18 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 29% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of QUANTUM LEAP HEALTHCARE COLLABORATIVE’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
QUANTUM LEAP HEALTHCARE COLLABORATIVE has a broad base — no single funder exceeds 27% of grant income, and it takes 3 funders to reach half.
the vertical line marks half of all grant income — 3 funders to its left
57% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund QUANTUM LEAP HEALTHCARE COLLABORATIVE.
Largest funder’s share by year: 2017 89% · 2018 43% · 2019 97% · 2020 44% · 2021 41% · 2022 75% · 2023 57% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
18% of QUANTUM LEAP HEALTHCARE COLLABORATIVE's funders are still giving 3 years after their first grant; 44% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
94% of QUANTUM LEAP HEALTHCARE COLLABORATIVE's grant income comes from California funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $765k arriving through sponsors registered in 7 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
QUANTUM LEAP HEALTHCARE COLLABORATIVE has grown faster than three-quarters of the 3,289 human services nonprofits its size.
this organization peer median middle 50% of peers· 3,289 human services nonprofits $10M–$100M, FY2024
Organizations like QUANTUM LEAP HEALTHCARE COLLABORATIVE
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In California
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
88% of spending goes to programs.
Governance
Public support
95%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for QUANTUM LEAP HEALTHCARE COLLABORATIVE: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds QUANTUM LEAP HEALTHCARE COLLABORATIVE?
- QUANTUM LEAP HEALTHCARE COLLABORATIVE (California) receives grants from 18 organizations whose IRS filings report $2,668,971 to it, the largest being THE ALBERTSONS COMPANIES FOUNDATION ($730,000). 8 of them have funded it in more than one year.
- How many funders does QUANTUM LEAP HEALTHCARE COLLABORATIVE have?
- IRS filings report 18 organizations giving $2,668,971 in grants to QUANTUM LEAP HEALTHCARE COLLABORATIVE, 8 of which have funded it in more than one year.
- Who is the largest funder of QUANTUM LEAP HEALTHCARE COLLABORATIVE?
- THE ALBERTSONS COMPANIES FOUNDATION is the largest funder on record, with $730,000 in grants. The full list of funders is on this page.
- How can an organization like QUANTUM LEAP HEALTHCARE COLLABORATIVE find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in California. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 18 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing